LAS VEGAS, Nov. 6, 2006 (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. and Samaritan Pharma Ireland, Inc. (AMEX:LIV) developers of innovative drugs, announced today it has submitted an Investigational New Drug (IND) application to evaluate its lead compound Caprospinol (SP-233) as a potentially new and novel pharmaceutical treatment for Alzheimer’s disease. This is an important first step, to test Caprospinol’s future in humans, as a potential memory-saving Alzheimer’s drug.
